Notice ID: 4210f679b0374beca20791a1ccdecbadCombined Synopsis/Solicitation
VirScan Analysis on Plasma samples
Archived on August 25, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 9:00 AM UTC−04:00
- Posted
- August 14, 2020
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NICHD
- Place of performance
- Baltimore, MD, 21205
- Last updated
- Apr 29, 2026
Identifiers
- Solicitation number
- NICHD-20-248
- Notice ID
- 4210f679b0374beca20791a1ccdecbad
Description
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NICHD-20-248 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2020-08. The North American Industry Classification (NAICS) Code is 541990 and the business size standard is $16.5m. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intend to procure on a sole source basis with CDI Laboratories @ Baltimore, MD services to process human patient plasma sample using their proprietary VirScan Analysis procedure. Background: In the Study 20-AA-N115 COVID-19 Pandemic Impact on Alcohol (PIA) A Natural History Study we are assessing the impact of the COVID-19 Pandemic on Alcohol use in a deeply phenotyped sample of NIAAA patients. Phenotyping means collecting information from the patient about their drinking history, physical characteristics, socially economic status, etc. The Virscan assay will allow us to determine if a local subset of our sample of patients was exposed to the Coronavirus causing the COVID-19 infection in the context of seropositivity for other Type A and Type B coronaviruses, and >100 other viruses. It is already known that heavier drinkers have different immune responses, such as cytokine inflammatory signal molecules. This viral history data will provide unique information how those who drink heavily differ from the general population when analyzed with the phenotyping information. The ANTYGEN VirScan service, developed by CDI from Dr. Elledges initial research and creation, provides a unique way to assay a patients viral history by analyzing antiviral antibodies to a phage library displaying peptides from 206 species and over 1000 strains of viruses. Typically, such tests measure only one virus at a time. Using a synthetic representation of all human viral peptides, this blood test identifies antibodies against all known human viruses. No other known product can achieve this level of detection in a single blood sample. To achieve the same amount of data, more patient sample would be required in order to run multiple single-assay tests, which may exceed the volume of blood allowed to be collected with IRB approval. Additional cost, time, and staff workload would be required if results were collected by those other traditional methods. In reagents alone, a PCR test can cost thousands of dollars per molecule of study, which would limit our choice of targets compared to the Virscan comprehensive assay. The Virscan technique was developed by Dr. Steve Elledges Harvard laboratory. Dr. Elledge is on CDIs scientific advisory panel and has licensed CDI to market the commercial application of his research. Only CDI can provide this service. Service Provided: CDI will accept human patient plasma samples from an IRB approved NIAAA clinical study. They will process samples using their proprietary Virscan procedure which identifies every virus annotated to have human tropism in the UniProt database. [https://cdi.bio/antygen-virscanphip- seq-service/] This service includes: VirScan Analysis (>1000 individual strains across 206 unique viral species with known human tropism) of 240 serum samples, plus analysis of SARS-CoV-2 antibodies to S1 receptor binding spike & nucleocapsid proteins using CDI's SARS-CoV-2 Minichip. Combined assay (VirScan + SARS-CoV-2 minichip. Additionally, CDI will provide data for 20 serum samples on HuScan full human proteome assay for autoantibodies. Data will be sent to NIHs office for additional statistical analysis The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. Only one responsible source and no other supplies or services will satisfy agency requirements. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors Commercial Items; FAR Clause 52.212-2, Evaluation Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions applies to this acquisition. NOTE TO CONTRACTOR: The contractor shall provide a completed copy of FAR 52.204-24, "Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment" with their quote in response to this solicitation. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Vendors capable of furnishing the government with the services and or items specified in this synopsis should submit a copy of their quotation/offer to the following email address: robinsti@mail.nih.gov Attn: Tina Robinson by the due date and time below. Offers must also be accompanied by descriptive literature, warranties and/or other information that demonstrates that the offer meets all the foregoing requirements. Offeror must include the delivery date/timeframe with offer. Quotations will be due seven calendar days from the publication date of this synopsis before August 20, 2020 before 9:00 am EST. The quotation must reference Solicitation number NICHD-20-248 and Solicitation number NICHD-20-248 must be on/in subject line of email. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Any questions must be sent via email to robinsti@mail.nih.gov and must include Solicitation# NICHD-20-248 in the subject line of email. Note: In order to receive an award, contractor must be registered as all awards and have valid certification in the System for Award Management (SAM) @ www.Sam.gov. Lack of valid registration in SAM will make an offeror ineligible for award.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
NICHD-20-248- Combined Synopsis
- Combined SynopsisCurrentAug 14, 2020
VirScan Analysis on Plasma samples
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Small Businesses interested and capable of providing the services described below. NIH-OD-SS-27-000058 The information gained from this market research will help the National Institutes (NIH) Clinical Center (CC) plan for its acquisition strategy. Potential Large and Small Businesses shall include business information outlined in the section below as a part of their response. Complete responses to this notice shall be in the following format: SAM UEI Number and CAGE code Company Name Company Address, City, State and Zip Code Company Point of Contact, Email Address and Telephone Number Current GSA Schedule appropriate to this Sources Sought of other FAR Part 8 considerations Socioeconomic Status: (i.e., HUBZone, 8a, Small Business, Women Owned Small Business, Veteran-Owned Small-Business, etc.) https://www.sam.gov. Provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described in the Statement of Work. The NIH Clinical Center Office of Research Support and Compliance (ORSC) is seeking a qualified and experienced contractor to provide project management and coordination of routine and emergent qualification, calibration/PM and certification services, including repairs and replacements, for the departments/ICs located at the NIH’s Bethesda, MD campus. Please see attached SOW for more details. Contractors shall not reach out to the customer for any questions or clarifications. All communications must go through contracting. ****************************************************************************** Important information: The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. NAICS: The North American Classification System (NAICS) code for this acquisition is 541380. PSC: H966 Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered and have an active registration in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). All interested Offerors should submit information by e-mail to ryssa.nix@nih.gov. Please use subject line “Response to NIH-OD-SS-27-000058”. All information submissions shall be received no later than noon on November 15, 2026. | - | Pre-Solicitation | 11/15/2026 |
INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Alcami Corporation 2320 Scientific Park DR Wilmington, North Carolina 28405-1800 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541380 with a Size Standard $16.6M. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Background Information: NHGRI was gifted 48kg of unlabeled drug ManNAc (powder-in-sachet) in September 2025, and agreed to take over the FDA-required, mandatory, stability testing program of this drug that has been ongoing at Alcami Corporation since June 2024. The gifted drug was produced in 2 campaigns, Campaign 5 (C5, June 2024) and Campaign 6 (C6, September 2024). NHGRI plans to use the donated clinical grade drug for upcoming clinical trials. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by November 9, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98027Q00040. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.” | - | Pre-Solicitation | 11/09/2026 |
Centers for Disease Control (CDC) is issuing this synopsis as a means of conducting market research to identify parties having an interest in and the resources to support this requirement for a California-based integrated health care system to serve as an electronic health record site in CDC’s VISION 2.0 respiratory pathogen surveillance network, providing integrated, longitudinal medical, laboratory, pharmacy, vaccination, claims, and outcomes data to support influenza surveillance, vaccine-effectiveness studies, and related respiratory pathogen research across emergency/urgent care, inpatient, and intensive care unit (ICU) settings. The result of this market research will contribute to determining the method of acquisition. The applicable North American Industry Classification System (NAICS) code assigned to this acquisition is 541380- Testing Laboratories and Services. | - | Market Research | 12/04/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01209/PCA-NIA-08501. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Epigenetic Clock Development Foundation 1124 W. Carson Street, MRL Bldg., 3rd Floor Torrance, CA 90502 US to provide obtain DNA methylation profiling and epigenetic age analysis for 320 previously extracted murine DNA samples using the Mammal320K methylation array and established Horvath epigenetic clock methodologies. | - | Combined Synopsis | 09/23/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01212/PCA-NIA-08124. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Metabolon Inc. 617 Davis Drive, Suite 100, Morrisville, NC 27560 to assay global metabolomics data and short chain fatty acids (SCFA) via the Metabolon platform from 369 blood samples in the BLSA. These metabolomics data will be used to identify metabolomic signatures of anthropometric aging quantified via a 3D body scanner. | - | Combined Synopsis | 09/23/2026 |
Additional Details
Solicitation Number
NICHD-20-248
Archive Date
Aug 25, 2020
Office Address
BETHESDA, MD, 20817